Effects of Donepezil on Central Processing Speed and Attentional Measures in Parkinson’s Disease with Dementia and Dementia with Lewy BodiesRowan E. · McKeith I.G. · Saxby B.K. · O’Brien J.T. · Burn D. · Mosimann U. · Newby J. · Daniel S. · Sanders J. · Wesnes K.
aInstitute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, bCognitive Drug Research Ltd., CDR House, Goring-on-Thames, UK
Background: We examined attention-enhancing effects of the cholinesterase inhibitor donepezil in Dementia with Lewy bodies (DLB) and Parkinson’s disease with dementia (PDD) by means of open label study. Methods: 22 DLBs and 23 PDDs were assessed over 20 weeks using the Cognitive Drug Research Computerized Attentional Tasks. We examined how much closer our patients moved towards being normal for their age by comparing them to a non-demented elderly control sample (n = 183, aged 71–75 years). Results: Donepezil treatment improved power of attention, continuity of attention and reaction time variability. The deficit in responses was moved towards normal by 38 and 56% for power of attention and 22 and 10% for continuity of attention in PDD and DLB, respectively. Conclusions: Improvements in attention were found with donepezil in PDD and DLB.
Ian G. McKeith
Institute for Ageing and Health
Newcastle General Hospital, Westgate Road
Newcastle upon Tyne, NE4 6BE (UK)
Tel. +44 191 256 3018, Fax +44 191 219 5071, E-Mail email@example.com
Published online: December 28, 2006
Number of Print Pages : 7
Number of Figures : 1, Number of Tables : 1, Number of References : 22
Dementia and Geriatric Cognitive Disorders
Vol. 23, No. 3, Year 2007 (Cover Date: February 2007)
Journal Editor: Chan-Palay, V. (New York, N.Y.)
ISSN: 1420–8008 (print), 1421–9824 (Online)
For additional information: http://www.karger.com/DEM